The development of chemotherapeutic agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection has focused primarily on two viral enzymes, reverse transcriptase (RT) and protease, and on the viral entry/fusion step (15, 31). Highly active antiretroviral therapy, consisting of multiple drug regimens attacking different targets and steps in the viral life cycle, has profoundly suppressed the levels of plasma viremia in patients infected with HIV-1, preventing opportunistic infections and reducing patient mortality. However, the emergence of multidrug-resistant variants remains problematic, suggesting the requirement for new antiviral agents (18, 20) . Integrase (IN) inhibitors, targeting a key enzyme of HIV-1 essential for its replication and persistence in the host genome, are one of the most promising classes of anti-HIV compounds. Importantly, two of them recently completed phase II clinical trials
The development of chemotherapeutic agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection has focused primarily on two viral enzymes, reverse transcriptase (RT) and protease, and on the viral entry/fusion step (15, 31) . Highly active antiretroviral therapy, consisting of multiple drug regimens attacking different targets and steps in the viral life cycle, has profoundly suppressed the levels of plasma viremia in patients infected with HIV-1, preventing opportunistic infections and reducing patient mortality. However, the emergence of multidrug-resistant variants remains problematic, suggesting the requirement for new antiviral agents (18, 20) . Integrase (IN) inhibitors, targeting a key enzyme of HIV-1 essential for its replication and persistence in the host genome, are one of the most promising classes of anti-HIV compounds. Soon after infection and reverse transcription, viral linear DNA is transported into the nucleus of the infected cell, where it may either integrate into the host cell's genome or remain extrachromosomal and circularize to form episomes containing either one or two long-terminal repeats (one-LTR or two-LTR circles) (8) . The integration step is a process dependent on the viral IN enzyme, which is essential for the subsequent steps of viral replication (8) . Thus, integration of the viral genome into the cell's chromosome is a crucial step for completion of the HIV-1 life cycle, and its inhibition is an attractive target for anti-HIV drug development (32) . By preventing integration, the anti-IN compounds preclude the subsequent steps of viral replication and spread while allowing the production of the extrachromosomal forms of viral DNA (E-DNA) (17, 26, 28, 40, 41) . This recapitulates the effects obtained in cell cultures after infection with IN-defective viruses, which produce only E-DNA in the absence of integrated provirus (1, 5, 11) . Importantly, E-DNA has been shown to be transcriptionally active, albeit at lower levels than its integrated counterpart, producing only spliced RNA for the viral proteins Env, Tat, Rev, and Nef (14, 46) .
Until recently, high-throughput screening for potential IN inhibitors has been performed primarily in cell-free systems, using purified IN protein either alone or within the context of a partially purified preintegration complex (12, 16, 17, 19) . However, inhibitors identified in this manner are frequently cytotoxic or do not exhibit antiviral activity in cell culture (29, 33) . Conversely, the cell culture-based HIV-1 drug susceptibility assay in use measures the extent to which a drug inhibits HIV-1 p24 antigen production in peripheral blood mononuclear cells (PBMC) or HIV-permissive T-cell lines acutely infected with viral isolates or laboratory-adapted viruses, such as HIV-1 IIIB . The limitations of this assay concern the use of PBMC, with the consequent variability among different donors, the requirement for infectious virus and different virus inocula, and the costs and time involved. In addition, when potential IN inhibitors exhibit antiviral activity in this system, the molecular target of virus inhibition may not be solely the integration reaction, and further analyses need to be performed.
During the past few years, several authors have described different assays that can be used to evaluate potential IN inhibitors in cell culture systems. These methods are based on the detection and quantification of integrated HIV-1 DNA, eventually in combination with the quantitative analysis of the two-LTR circular forms of E-DNA (2, 4, 41, 42) . These assays, usually based on Alu nested or real-time DNA PCR, have the advantage of specifically evaluating HIV-1 integration in the presence or absence of a given compound but require expensive instruments and advanced technology. More recently, a luciferase-based assay relying on a single-cycle infectious virus for testing antiviral activities of compounds has been reported (40) .
Here, we report on the development and standardization of a 96-well microtiter assay to evaluate the potential anti-IN activities of new compounds in a cell-based system by taking advantage of the transcriptional activities of IN-competent and IN-defective HIV-derived vectors expressing the luciferase reporter gene, mimicking the parental virus life cycle in the absence of replication-competent virus. By using this method, we evaluated several potential novel compounds with in vitro anti-IN activity and found that three of them possessed strong activity in cell culture in the absence of cellular toxicity.
coding sequence of luciferase (44) was cloned in place of green fluorescent protein (GFP) to produce the TY-CMV-Luciferase plasmid. A BssHII/ClaI fragment from the pHRЈcPPT plasmid, containing the central polypurine tract (cPPT) and a shorter packaging signal (⌿), was inserted in the corresponding sites of the TY-CMV-GFP and TY-CMV-Luciferase plasmids to obtain the self-inactivating TY2-CMV-GFP and TY2-CMV-Luciferase lentiviral vectors. Plasmid pCHelpIN Ϫ , kindly provided by J. Reiser, produces all HIV-1 viral proteins, with the exception of Env. In addition, the IN produced by the pCHelpIN Ϫ plasmid contains a point mutation in the middle of a reading frame of the IN protein (D116N), preventing the functions characteristic of the IN protein, as previously described (11, 44) . Plasmid pCMV⌬R8.2 (27) We chose the quinolinone skeleton because (i) the activity and safety of 4(1H)-quinolinone derivatives as antibacterial agents are well known and (ii) this structure is useful to obtain a high number of congeners to be tested in biological assays (10) . The synthesis, structure-activity relationships, and molecular-modeling studies of these novel anti-IN agents will be reported elsewhere.
In vitro HIV-1 recombinant integrase assay. Compounds were evaluated for their IN inhibition in a gel-based assay as described previously (25) . In the assay, a 5Ј-end-labeled 21-mer double-stranded DNA oligonucleotide corresponding to the last 21 bases of the U5 viral LTR was used to follow both the 3Ј-processing and strand transfer steps of the integration reaction (32) . Briefly, a DNA-enzyme complex was preformed by mixing 500 nM of recombinant HIV-1 IN and 20 nM of 5Ј-labeled double-stranded DNA template in a buffer containing 50 mM MOPS (morpholinepropanesulfonic acid), pH 7.2, 7.5 mM MnCl 2 , and 14.3 mM ␤-mercaptoethanol for 15 min on ice. The integration reaction was then initiated by addition of each compound and continued in a total volume of 10 l for 60 min at 37°C. The reaction was stopped by adding the same volume of electrophoresis denaturing dye, containing 99% formamide (Sigma-Aldrich, Milwaukee, WI), 1% sodium dodecyl sulfate, 0.2 mg/ml bromophenol blue (Sigma-Aldrich, Milwaukee, WI), and 0.2 mg/ml xylene cyanol blue (Sigma-Aldrich, Milwaukee, WI). Samples were loaded on a 20% 19:1 acrylamide-bis-acrylamide denaturing gel (Accugel; National Diagnostics, Atlanta, GA) containing 7 M urea (Gibco BRL Life Technologies, Rockville, MD) in 1ϫ Tris-borate-EDTA (Gibco BRL Life Technologies, Rockville, MD). The gels were exposed overnight and analyzed using a Molecular Dynamics (Sunnyvale, CA) PhosphorImager.
Lentiviral-vector production and 293 cell transduction. Lentiviral vectors were produced in 293 cells by a calcium phosphate transient-transfection method as previously described (27) . Briefly, the day before transfection, cells were plated at a density of 3 ϫ 10 6 in a 100-mm-diameter petri dish at 80% confluence. A total of 28 g of plasmid DNA was used for each plate in a 3:2:0.7 (transfer vector-packaging vector-envelope vector) ratio using the calcium phosphatebased Profection Mammalian Transfection System (Promega Corporation, Madison, WI). After 48 h, the viral supernatants were collected, spun at 1,500 rpm, and passed through a 0.45-m-pore-size filter. Supernatants containing recombinant viruses were normalized for RT activity using standard radioactive methodologies (45) . 
RESULTS
HIV-1 drug susceptibility assay on PBMC. The HIV-1 drug susceptibility assay measures the extent to which a given compound inhibits HIV-1 p24 antigen production on PHA-stimulated PBMC from normal donors acutely infected with a HIV-1 molecular clone, a laboratory-adapted or primary isolate.
For HIV-1 drug susceptibility assay validation in our model system, we tested the abilities of known antiviral compounds, the DKA IN inhibitor L-731,988 (17) and two RT inhibitors, zidovudine (AZT) and dideoxyinosine (ddI), to inhibit p24 release in the supernatants of PHA-stimulated HIV-1 IIIB -infected PBMC. Following infection, p24 antigen release in the cell culture supernatants was evaluated on day 7, and the IC 50 s and IC 90 s of the drugs were determined using the median effect equation (7) . As shown in Fig. 2 (17, 22, 24, 37, 42) . Drug toxicity was tested by cell viability, using the trypan blue exclusion method, and was found to be negligible at the indicated IC 50 s and IC 90 s (Fig. 2) .
The IN inhibitor L-731,988 does not hinder expression from unintegrated templates. Recently, a few reports showed that viral proteins are expressed in the presence of anti-IN DKA compounds due to the transcriptional activity of E-DNA (14, 46) . To validate this assumption in our model system, we per- 
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sion proportional to the increase in the L-731,988 concentration ( Fig. 3a and Table 1 ). Conversely, GFP expression remained stable in the IN-defective lentiviral-vector-infected cells regardless of the anti-IN inhibitor concentration, confirming a steady transcriptional activity, albeit lower than that of the integrated counterpart of E-DNA, as previously reported ( Fig. 3b and Table 1 ) (3, 14, 46) . Similar to what has been found by other groups (4, 17, 40, 42) , the presence of E-DNA was confirmed by two-LTR amplification of DNA extracted from the infected cells, using a primer pair spanning the junction between the two LTRs, as described previously (44), indicating that production of E-DNA was not affected by the IN inhibitor, allowing GFP expression from unintegrated viral templates (data not shown).
Use of lentiviral vectors expressing luciferase in 293 cells for evaluation of IN inhibitors.
To extend this system, we set up a high-throughput system for ex vivo analysis of compounds with known in vitro anti-HIV activities, using a microtiter plate format based on luciferase activity, allowing a rapid and sensitive evaluation of viral inhibitors on 293 cells. To this end, 293 cells were seeded in a 96-well white plate with a clear bottom and infected with equal amounts of IN-competent and INdefective TY2-CMV-Luciferase lentiviral vectors. At the time of infection, increasing amounts of the IN inhibitor L-731,988 (range, 0.5 to 50 M) and the RT inhibitors AZT (range, 10 to 1,000 M) and ddI (range, 0.0005 to 10 M) were added to the medium. Four hours postinfection, the medium was removed and replaced with fresh medium supplemented with each drug. After 72 h, the luciferase activity was evaluated directly on the 96-well white plate. Following data analysis, the IC 50 s and IC 90 s in both the IN-competent and IN-defective TY2-CMVLuciferase-infected cells were calculated. As shown in Fig. 4a , luciferase values decreased in the IN-competent TY2-CMVLuciferase-infected cells with increasing amounts of L-731,988, confirming the results obtained with the IN-competent TY2-CMV-GFP HIV-derived vector. Importantly, the calculated IC 50 and IC 90 values were 6.6 M and 40.7 M, respectively, both in the same log range of activity attained in the PBMC experiment (Fig. 4) . In particular, luciferase expression decreased proportionally to the increase in drug concentrations, declining over 22- Compound toxicity was tested using the trypan blue exclusion method and was found to be negligible (below 10%) at the indicated IC 50 and IC 90 (data not shown).
As a further control to validate IN as the molecular target accountable for the antiviral activity in our system, the two nucleoside analogues, AZT and ddI, that interfered with viral reverse transcription, a step preceding nuclear import and circle formation, were tested in the same system. As shown in Fig.  4b and c, luciferase activity decreased with increasing amounts of either AZT or ddI in both the IN-competent and IN-defective lentiviral-vector-infected cells in the absence of evident cellular toxicity, indicating that drugs that inhibit the reversetranscription step preceding E-DNA synthesis do not allow transcription from unintegrated templates. However, in the 293 cell system, a larger amount of each drug was necessary to reach measurable IC 50 and IC 90 values than in the HIV-1 drug susceptibility assay performed on PBMC, suggesting that 293 cells are somewhat refractory to nucleoside analogue internalization (Fig. 1) .
A luciferase-based assay for the evaluation of new DKAderived compounds. The anti-IN activities of DKA-derived compounds were measured by standard biochemical assays ( Table 2 ). The results indicated that all tested compounds were potent IN inhibitors in enzyme assays and were selective against strand transfer versus 3Ј-processing reactions, as has been described with most DKA-derived compounds (47) . In general, preliminary structure-activity relationships referred to strand transfer reaction, leading us to conclude that (i) the acids (RDS 1625, RDS 1984, RDS 2161, and RDS 2164) were 10 to 100 times more potent inhibitors than the corresponding esters (RDS 1624, RDS 1983, RDS 2160, and RDS 2163), (ii) the 2,6-F2 derivatives were more potent inhibitors than the 4-F derivatives, (iii) the 2-OCH3 derivatives were 4-to 10-fold more active than their 3-OCH3 counterparts, and (iv) the shift of the DKA chain of RDS 1625 in the 6 position of the quinolinone ring led to compound RDS 1607, which showed a decreased inhibitory activity compared to that of the parental compound. Interestingly, three out of nine derivatives were more potent than the reference compound, L-731,988.
Subsequent to the in vitro analysis, all compounds were evaluated for antiviral activity by comparing the HIV-1 drug susceptibility assay performed on PBMC and the luciferase-based assay described above. First, all compounds were tested on PBMC (range, 1.0 M to 50 M), using the in vitro HIV-1 drug susceptibility assay. As shown in Table 2 We further evaluated all compounds with our luciferasebased system by infecting 293 cells with equal amounts of IN-competent and IN-defective lentiviral vectors expressing luciferase. The reference drug, L-731,988, was added under the same conditions previously tested, while the range of concentrations used for all the other compounds was 1.0 M to 50 M (Fig. 5) . Seventy-two hours later, luciferase activity was evalu- In this setting, the use of an IN-defective lentiviral vector expressing a reporter gene allowed us to evaluate whether the anti-IN compounds under analysis were acting at steps prior to circle formation. In fact, following infection of 293 cells with the IN-defective lentiviral vector, E-DNA production and GFP and luciferase expression did not change in the presence of IN inhibitors in the absence of cellular toxicity. This was as expected in the presence of a true IN inhibitor. In contrast, compounds such as AZT or ddI, acting at steps preceding circle formation, had the same effect on E-DNA production from IN-competent or IN-defective viruses, since E-DNA synthesis was inhibited (13, 23, 30, 38, 39) and luciferase expression fell to negligible levels. This assay was validated by comparative evaluation with the HIV-1 drug susceptibility assay performed on PBMC. IC 50 activity had been first demonstrated using biochemical assays. Using the well-known anti-IN drug L-731,988 as the reference control, all the new compounds were tested in the HIV-1 drug susceptibility assay of PBMC in comparison with 293 cells infected with the luciferase-expressing lentiviral vectors. The results showed that only compounds RDS 1625, RDS 1983, and RDS 1984 confirmed their activities as IN inhibitors in both assays, while all other compounds were either unable to block HIV-1 IIIB replication in the drug susceptibility assay of PBMC or ineffective in reducing luciferase expression in the 293 cell-based system. These data confirm the need to evaluate in a cell-based assay compounds previously tested in vitro and further confirm the validity of the method we described.
In conclusion, the microtiter assay for the detection of IN inhibitors described here allows high reproducibility and standardization, avoiding the limitation of donor variability and thus providing a uniform and cost-effective method for the evaluation of novel anti-IN compounds. Moreover, the use of HIV-1-derived vectors (IN competent and IN defective) avoids the requirement for handling infectious HIV-1, since lentiviral vectors are competent to infect target cells but do not support further rounds of viral replication. In addition, since these vectors mimic the HIV-1 life cycle, including the formation of E-DNA (43, 44) , the use of IN-defective virus expressing luciferase allows investigators to check whether the anti-IN compounds under evaluation are acting at steps prior to circle formation. Finally, the presence of the firefly luciferase gene as a reporter gene provides a rapid, sensitive, and quantitative measure of virus infectivity and expression.
